🧪
hypothesis

Lysosomal GBA1 Enhancement via Glucosylceramide Reduction

Hypothesis

Lysosomal GBA1 Enhancement via Glucosylceramide Reduction

GBA1 mutations increase α-synuclein aggregation risk through glucosylceramide accumulation.
🧬 GBA1🩺 neurodegeneration🎯 Composite 80%💱 $0.64▼18.5%proposed
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.80 (15%) Evidence 0.88 (15%) Novelty 0.55 (12%) Feasibility 0.82 (12%) Impact 0.85 (12%) Druggability 0.88 (10%) Safety 0.75 (8%) Competition 0.65 (6%) Data Avail. 0.82 (5%) Reproducible 0.78 (5%) KG Connect 0.50 (8%) 0.800 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite80%

🧪 Overview

GBA1 mutations increase α-synuclein aggregation risk through glucosylceramide accumulation. Enhancement of GCase activity via chaperone therapy (ambroxol) or substrate reduction (GCS inhibitors) represents the strongest therapeutic approach with active clinical trials, favorable safety profile, and FDA orphan designation for genetically-defined PD subtype.

🧬 Mechanism

No curated mechanism pathway recorded for this hypothesis.

⚖️ Evidence

⚖️ Evidence Matrix4 supports3 contradicts
Supports
GBA1 mutations confer OR 5-7 for PD risk
PMID:19640974
Supports
Glucosylceramide accumulation promotes α-synuclein fibrillization in vitro
PMID:25556532
Supports
Ambroxol Phase II trial ongoing at UCL
PMID:clinicaltrials.gov-NCT02941866
Supports
GCase activity inversely correlates with PD risk in non-carriers
PMID:31155476
Contradicts
GBA1 haploinsufficiency alone insufficient to cause PD in most carriers
PMID:24789722
Contradicts
Glucosylceramide elevation may be downstream effect rather than causative
PMID:30336208
Contradicts
Venglustat Phase II paused (2022) for lack of efficacy signal
PMID:Sanofi-2022
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — GBA1

🧬 PDB 2V3D Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GBA1 →

No DepMap CRISPR Chronos data found for GBA1.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
↘
Falling
7d Momentum
▼ 2.1%
Volatility
Low
0.0026
Events (7d)
3
Price History
▼18.5%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

View on SciDEX ↗